Innovative BATTLE Trials Pair Agents, Biomarkers in NSCLC

Anita T. Shaffer @Shaffer1
Published: Thursday, Feb 07, 2013

Pathways Targeted in BATTLE-2

Growth Factor Pathways
Targeted agents under study are shown in blue boxes.
Adapted from Herbst RS. Targeting the PI3K/AKT axis: what lies ahead in lung cancer.
Presented at: 13th International Lung Cancer Congress; Huntington Beach, CA; July 19-22, 2012.
As therapy based on cell-signaling pathways has become a priority in cancer research, so has the concept of designing clinical trials that can better target patient populations more likely to benefit from a particular regimen.

“We felt the traditional way of testing drugs in combination with chemotherapy was not going to really help us move these drugs forward,” said principal investigator Edward S. Kim, MD, in an interview posted on MD Anderson’s website. Kim, now chair of the Department of Solid Tumor Oncology and Investigational Therapeutics at Carolinas HealthCare System’s Levine Cancer Institute, added, “We felt it was more important to really focus on the patient⎯finding what was unique about that patient’s tumor.”

Choosing Therapies for First Trial

Four promising molecular targets were identified: endothelial growth factor receptor (EGFR), Ras/Raf, retinoid X receptor (RXR)/cyclin D1, and vascular endothelial growth factor (VEGF) or the angiogenesis cascade.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Online Medical Crossfire®: 5th Annual Miami Lung Cancer ConferenceMay 30, 20196.5
Community Practice Connections™: Working Group for Changing Standards in EGFR-Mutated Lung Cancers: Real-World Applications of the Evidence for NursesJun 29, 20191.5
Publication Bottom Border
Border Publication